Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kingdon, H. S.
Right arrow Articles by Hassell, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kingdon, H. S.
Right arrow Articles by Hassell, T. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions

HS Kingdon and TM Hassell

Therapeutic effectiveness of factor VIII inhibitor bypassing materials has been evaluated in dogs with hemophilia A. A standardized template gingival biopsy was performed using local anesthesia. Hemophilic dogs bled extensively from the biopsy site, whereas in normal dogs the wound was sealed within 5 + /- 2 min. If untreated, the hemophilic dogs frequently bled for several days. Factor VIII infusion stopped the bleeding promptly. Some experimental preparations of factor VIII inhibitor bypassing materials were shown to be therapeutically effective, whereas others were not. Intravascular thrombi could not be demonstrated histologically. The model should prove useful for evaluating factor VIII inhibitor bypassing materials and also for evaluating their mechanism of action.

Volume 58, Issue 5, pp. 868-872, 11/01/1981
Copyright © 1981 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
H. R. Roberts, D. M. Monroe, and G. C. White
The use of recombinant factor VIIa in the treatment of bleeding disorders
Blood, December 15, 2004; 104(13): 3858 - 3864.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. W. Russell and M. A. Kay
Adeno-Associated Virus Vectors and Hematology
Blood, August 1, 1999; 94(3): 864 - 874.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1981 by American Society of Hematology         Online ISSN: 1528-0020